Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced recurrent or metastatic lung squamous cell carcinoma
ChiCTR1900020917Phase 2Not yet recruiting
- Sponsor
- The First People's Hospital of Yueyang
- Start
- Jun 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib and docetaxel in Pulmonary squamous cell carcinoma (2 arms), sponsored by The First People's Hospital of Yueyang. Primary endpoints: Objective response rate and Disease control rate. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
anlotinibdocetaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1900020917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020917.